Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Lilly's $2.88 Billion Immunology Deal Starts in Phase 1
1+ week, 6+ day ago (205+ words) The milestone-heavy purchase adds a broad scientific platform, but its lead medicine remains at the earliest clinical stage. Oops, something went wrong U.S. markets close in 5h 58m Lilly's $2.88 Billion Immunology Deal Starts in Phase 1 This article first appeared on GuruFocus. Eli Lilly…...
Transgene jumps 20% on positive cancer vaccine data in early trial
1+ week, 3+ day ago (191+ words) Sept 3 (Reuters) – Transgene shares surged 20% in early Paris trading on Thursday, after the French biotechnology company reported positive Phase 1 trial data on its vaccine candidate for head and neck cancer. Investors have rewarded encouraging data from other personalised cancer-vaccine programmes…...
Lilly adds Merida's autoantibody-degrading tech to immunology arsenal for up to $2.9B
1+ week, 6+ day ago (14+ words) FirstWord Pharma...
Inside Moderna and Merck's cancer vaccine breakthrough
2+ week, 13+ hour ago (91+ words) Xavier Martinez, News Associate at The Wall Street Journal, breaks down Moderna’s mRNA ambitions, its pipeline beyond COVID-19 and the challenges ahead. Stephane Bancel, CEO of Moderna, was at a Lebanese restaurant celebrating a friend’s birthday late on Aug. 13 when…...
Melanoma Vaccine Data Breakthrough: Moderna Receives Fifth Analyst Upgrade in Five Days — BigGo Finance
2+ week, 2+ day ago (391+ words) U.S. biotech giant Moderna (MRNA) continues to ride a wave of momentum from clinical data on its melanoma mRNA cancer vaccine, prompting a notable shift in Wall Street analyst sentiment. Argus Research this week upgraded Moderna from "Hold" to "Buy," becoming…...
Was Moderna Stock’s 440% Surge Hiding In Plain Sight?
2+ week, 4+ day ago (392+ words) Forbes Was Moderna Stock’s 440% Surge Hiding In Plain Sight? Moderna (MRNA) shares have surged over the past year, with the event that more than doubled its valuation in a single trading day occurring on August 19, 2026. On that date, Merck and…...
MTRX Q4'26 Earnings: revenue estimate is 247.04M USD
2+ week, 4+ day ago (82+ words) TradingView MTRX Q4'26 Earnings: revenue estimate is 247.04M USD MTRX (Matrix Service Company) is set to announce its Q4'26 results on September 02, after the market closes. The earnings are expected to be disclosed at 4:00 PM ET (8:00 PM UTC). For Q4'26, revenue estimate is 247.04 million…...
Immatics: 'Buy' On 1st Half 2027 Catalyst, Potential Label Expansion For Uveal Melanoma
2+ week, 5+ day ago (106+ words) Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma Seeking Alpha - Immatics N.V. is rated "Buy," downgraded from "Strong Buy," due to partial partnership termination and pivotal trial dependency. - IMTX's investment thesis centers on anzu-cel [IMA203], a PRAME-directed…...
How the Merck/Moderna cancer vaccine works and possible barriers to wide use
2+ week, 5+ day ago (47+ words) Published on 08/25/2026 at 12:31 pm EDT Moderna Soars 129% for the Week | Closing Bell August 21, 2026 at 05:02 pm EDT Will Moderna Wake Up the Health Care Sector? Moderna and Merck & Co are the stocks of the day on Wall Street...
Moderna Added 45 Billion Dollars in a Day on a Melanoma Vaccine Result with No Effect Size Disclosed
2+ week, 5+ day ago (512+ words) Moderna and Merck reported that their personalized mRNA cancer vaccine succeeded in a Phase 3 melanoma trial. Moderna's market value rose by nearly $45 billion in a single session, with the two companies and rival BioNTech gaining around $92 billion collectively. Neither partner…...